Review of Non-Vitamin K Antagonist Oral Anticoagulants
Study Overview
A recent review has evaluated data from various studies regarding the efficacy and safety of a new class of drugs, known as non-vitamin K antagonist oral anticoagulants (NOACs), used for treating atrial fibrillation and venous thromboembolism. The findings suggest that NOACs are either superior to or on par with traditional vitamin K antagonist medications, specifically warfarin, for managing these conditions.
Understanding Atrial Fibrillation and Venous Thromboembolism
Atrial fibrillation is characterized by an irregular and often rapid heartbeat, significantly increasing the risk of blood clots, strokes, and heart failure. Venous thromboembolism, a serious vascular condition, involves clot formation in the veins that can lead to life-threatening complications if clots travel to the lungs, obstructing blood flow and causing damage to blood vessels. To mitigate the risks of clotting, patients are typically prescribed anticoagulants.
Warfarin: The Traditional Anticoagulant
Warfarin has been the standard anticoagulant prescribed for many years. It operates by inhibiting the enzyme vitamin K epoxide reductase, which decreases active vitamin K1 levels and subsequently reduces blood clotting capacity. Despite its effectiveness and lower cost, warfarin’s anticoagulation effects can be unpredictable, necessitating ongoing monitoring and dose adjustments.
Emergence of NOACs
The introduction of NOACs represents a significant advancement in anticoagulant therapy. Currently, four NOACs have received approval: dabigatran, which inhibits thrombin, and rivaroxaban, edoxaban, and apixaban, which act as factor Xa inhibitors. These medications are prescribed for the prevention of cardioembolic disease in patients with non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolism. Unlike warfarin, NOACs are fast-acting and do not require regular blood monitoring or dose adjustments, although questions regarding their efficacy and safety persist.
Recent Study Findings
A study published in *Clinical Therapeutics* in June 2017 systematically reviewed data from randomized control trials and observational studies to compare the efficacy and safety of NOACs with vitamin K antagonists. The research focused on publications dated from January 1, 2005, to February 15, 2016. It assessed the drugs’ effectiveness in reducing strokes and systemic embolism in atrial fibrillation patients and their ability to prevent recurrent venous thromboembolism and fatal pulmonary embolism. Major bleeding events during treatment were also analyzed to evaluate safety.
Evaluation Metrics
The evaluation metrics included occurrences of stroke types (ischemic and hemorrhagic), myocardial infarction (MI), and overall mortality rates to assess secondary effectiveness against atrial fibrillation. For venous thromboembolism, the study looked at recurrent deep vein thrombosis, nonfatal pulmonary embolism, and all-cause mortality. Secondary safety metrics included incidents of intracranial hemorrhage and gastrointestinal bleeding.
Study Results
The results indicated that NOACs were generally superior or comparable to vitamin K antagonists regarding both efficacy and safety. However, the risk profile varied among the four NOACs concerning bleeding events, MI, hemorrhagic stroke, overall mortality, and intracranial hemorrhage. Notably, the study found significant variability in major bleeding events, MI, all-cause mortality, and gastrointestinal bleeding for dabigatran, suggesting that differences in patient demographics and data sources may contribute to these discrepancies.
Study Limitations and Future Research
One limitation of the study was the exclusion of non-English language publications, which may impact the generalizability of the findings. Additionally, for apixaban and edoxaban, the analysis was based on data from a single randomized clinical trial without observational data. Therefore, further research is essential to comprehensively assess the safety and efficacy of these newer anticoagulant options.
Conclusion
By thoroughly analyzing the efficacy and safety of the NOAC class, this study addresses a critical gap in knowledge, potentially guiding evidence-based clinical decision-making and enhancing patient care.
Author Information
Written by Usha B. Nair, Ph.D.
References
Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-Analyses. Clin Ther. 2017 Jun 28. pii: S0149-2918(17)30699-9. doi: 10.1016/j.clinthera.2017.05.358. [Epub ahead of print] Review. PubMed PMID: 28668628.